These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26270389)

  • 1. Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study.
    Timp JF; Lijfering WM; Flinterman LE; van Hylckama Vlieg A; le Cessie S; Rosendaal FR; Cannegieter SC
    J Thromb Haemost; 2015 Oct; 13(10):1823-32. PubMed ID: 26270389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.
    Rietveld IM; Lijfering WM; le Cessie S; Bos MHA; Rosendaal FR; Reitsma PH; Cannegieter SC
    J Thromb Haemost; 2019 Jan; 17(1):99-109. PubMed ID: 30471183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study.
    Yap ES; Timp JF; Flinterman LE; van Hylckama Vlieg A; Rosendaal FR; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2015 Oct; 13(10):1833-42. PubMed ID: 26264493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
    Cosmi B; Legnani C; Cini M; Favaretto E; Palareti G
    Thromb Res; 2008; 122(5):610-7. PubMed ID: 18304616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
    van Hylckama Vlieg A; Baglin CA; Luddington R; MacDonald S; Rosendaal FR; Baglin TP
    J Thromb Haemost; 2015 Sep; 13(9):1642-52. PubMed ID: 26178257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
    Rauch A; Labreuche J; Lassalle F; Goutay J; Caplan M; Charbonnier L; Rohn A; Jeanpierre E; Dupont A; Duhamel A; Faure K; Lambert M; Kipnis E; Garrigue D; Lenting PJ; Poissy J; Susen S
    J Thromb Haemost; 2020 Nov; 18(11):2942-2953. PubMed ID: 32881304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study.
    Debeij J; van Zaane B; Dekkers OM; Doggen CJ; Smit JW; van Zanten AP; Brandjes DP; Büller HR; Gerdes VE; Rosendaal FR; Cannegieter SC
    J Thromb Haemost; 2014 Jun; 12(6):839-46. PubMed ID: 24679097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study.
    Morelli VM; Lijfering WM; Rosendaal FR; Cannegieter SC
    J Thromb Haemost; 2017 Apr; 15(4):695-701. PubMed ID: 28135040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism.
    Cristina L; Benilde C; Michela C; Mirella F; Giuliana G; Gualtiero P
    Br J Haematol; 2004 Feb; 124(4):504-10. PubMed ID: 14984502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of recurrent venous thromboembolism among patients with high factor IX levels.
    Weltermann A; Eichinger S; Bialonczyk C; Minar E; Hirschl M; Quehenberger P; Schönauer V; Kyrle PA
    J Thromb Haemost; 2003 Jan; 1(1):28-32. PubMed ID: 12871536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the DASH prediction rule: a retrospective cohort study.
    Tosetto A; Testa S; Martinelli I; Poli D; Cosmi B; Lodigiani C; Ageno W; De Stefano V; Falanga A; Nichele I; Paoletti O; Bucciarelli P; Antonucci E; Legnani C; Banfi E; Dentali F; Bartolomei F; Barcella L; Palareti G
    J Thromb Haemost; 2017 Oct; 15(10):1963-1970. PubMed ID: 28762665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP).
    Timp JF; Braekkan SK; Lijfering WM; van Hylckama Vlieg A; Hansen JB; Rosendaal FR; le Cessie S; Cannegieter SC
    PLoS Med; 2019 Oct; 16(10):e1002883. PubMed ID: 31603898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study.
    Bugnicourt JM; Roussel B; Tramier B; Lamy C; Godefroy O
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):699-701. PubMed ID: 17189302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
    Nossent AY; VAN Marion V; VAN Tilburg NH; Rosendaal FR; Bertina RM; VAN Mourik JA; Eikenboom HC
    J Thromb Haemost; 2006 Dec; 4(12):2556-62. PubMed ID: 17059421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis.
    Hoppener MR; Kraaijenhagen RA; Hutten BA; Büller HR; Peters RJ; Levi M
    J Thromb Haemost; 2004 Aug; 2(8):1316-20. PubMed ID: 15304037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma factor VIII in non-puerperal cerebral venous thrombosis: a prospective case-control study.
    Anadure RK; Nagaraja D; Christopher R
    J Neurol Sci; 2014 Apr; 339(1-2):140-3. PubMed ID: 24560376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors.
    Biguzzi E; Castelli F; Lijfering WM; Cannegieter SC; Eikenboom J; Rosendaal FR; van Hylckama Vlieg A
    Thromb Res; 2021 Jan; 197():172-178. PubMed ID: 33221577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study.
    Kreuz W; Stoll M; Junker R; Heinecke A; Schobess R; Kurnik K; Kelsch R; Nowak-Göttl U
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1901-6. PubMed ID: 16709943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
    Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
    Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII.
    Schambeck CM; Grossmann R; Zonnur S; Berger M; Teuchert K; Spahn A; Walter U
    Thromb Haemost; 2004 Jul; 92(1):42-6. PubMed ID: 15213843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.